Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 5

Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

November 1, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

Now Viewing

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Dr Ajai Chari to Dr Rossi: Can you please briefly review the currently available chimeric antigen receptor (CAR) T-cell therapies for early relapse multiple myeloma?
Dr Ajai Chari to Dr Rossi (then open to panelists): Where does CAR T-cell therapy currently fall in your treatment paradigm? Does it differ by product (cilta-cel vs ide-cel) or by high-risk features (minimal residual disease positivity post induction, extramedullary disease, etc)?